News GSK boosts anti-infectives pipeline with Scynexis antifungal Last year, GSK said it was planning to invest a cool £1 billion in infectious d
News BMS upgrades Evotec neurology alliance, now worth up to $4bn Bristol-Myers Squibb has expanded a long-running alliance with Evotec once again, paying another $50 million upfront to deepen their collaboration on drugs to treat neurod
News Roche, Lilly join forces on blood test for Alzheimer’s If approved, EAPP could help streamline the journey to diagnosis for patients, say partners.
News Gilead presses go on first Nurix protein degrader drug Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.
News Double blow for Sangamo as Novartis, Biogen exit deals The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.
News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
